Abstract：
Cardiovascular disease remains the leading cause of death globally, and heart failure (HF) represents its terminal stage. Asthma, one of the most common chronic diseases, has been reported to be associated with an increased risk of cardiovascular disease. However, the link between asthma and HF has rarely been studied, and the possible mechanisms by which asthma affects HF are unclear. This study aimed to explore the influence of asthma on HF and the possible mechanisms. We analyzed data from the National Health and Nutrition Examination Survey and found a higher prevalence of HF among asthmatic individuals, and identified an independent association between HF and asthma. Subsequently, we produced mice with concurrent ovalbumin (OVA) sensitization-induced allergic asthma and angiotensin Ⅱ infusion-induced cardiac remodeling to explore the effect of asthma on cardiac remodeling in vivo. The results showed that OVA-induced asthma impaired heart function and aggravated cardiac remodeling in mice. We also found that OVA sensitization increased the expression levels of immunoglobulin E (IgE) in serum and IgE receptor (FcεR1) in the heart, and enhanced the activation of downstream signaling molecules of IgE-FcεR1 in the heart. Importantly, blockage of IgE-FcεR1 using FcεR1-deficient mice or an anti-IgE antibody prevented asthma-induced decline of cardiac function, and alleviated cardiac remodeling. These findings demonstrate the adverse effects of allergic asthma on the heart, and suggest the potential application of anti-IgE therapy in the treatment of asthma complicated with heart conditions.
摘要：
心血管疾病仍然是全球死亡的主要原因，心力衰竭（HF）代表其终末期。哮喘,最常见的慢性疾病之一，据报道与心血管疾病的风险增加有关。然而,哮喘和HF之间的联系很少被研究，哮喘影响HF的可能机制尚不清楚。本研究旨在探讨哮喘对HF的影响及其可能的机制。我们分析了来自国家健康和营养调查的数据，发现哮喘个体中HF的患病率较高。并确定了HF和哮喘之间的独立关联。随后，我们制作了卵清蛋白（OVA）致敏诱导的过敏性哮喘和血管紧张素Ⅱ输注诱导的心脏重塑的小鼠，以探讨哮喘对体内心脏重塑的影响。结果表明，OVA诱导的哮喘会损害小鼠的心功能，加重心脏重塑。我们还发现OVA致敏增加了血清中免疫球蛋白E（IgE）和心脏中IgE受体（FcεR1）的表达水平，并增强了心脏中IgE-FcεR1下游信号分子的激活。重要的是,使用FcεR1缺陷小鼠或抗IgE抗体阻断IgE-FcεR1可预防哮喘引起的心功能下降，减轻心脏重塑。这些发现证明了过敏性哮喘对心脏的不利影响，提示抗IgE治疗在哮喘合并心脏病治疗中的潜在应用。
